- Algernon CEO Christopher J. Moreau will be speaking at the Psychedelic Capital Virtual Investment Conference
- The conference is presented by Microdose
- Mr Moreau, along with Dr. David Nutt, a DMT consultant, will be discussing the company’s DMT Stroke Clinical Research Program
- Algernon’s presentation will be held today at 4:45 pm EST
- Algernon is a drug re-purposing company that investigates safe, already approved drugs for new applications
- Algernon Pharmaceuticals (AGN) is down 1.45 per cent, trading at C$0.34 per share at 9 am EST
Algernon Pharmaceuticals Inc. (AGN), is pleased to announce that its CEO Christopher J. Moreau as well as Dr. David Nutt, one of the Company’s lead DMT consultants, will be discussing the Company’s new DMT Stroke Clinical Research Program at the upcoming Psychedelic Capital Virtual Investment Conference, presented by Microdose.
Algernon’s presentation at the virtual conference will be held today at 4:45 pm EST. The company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Algernon Pharmaceuticals (AGN) is down 1.45 per cent, trading at C$0.34 per share at 9 am EST.
